Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-02-12 | CymaBay Therapeutics, Inc. | Dorling Janet
(Director) |
S | Common Stock | D | 6000 | $31.97 - $31.97 | $191,848 |
| 2024-02-12 | CymaBay Therapeutics, Inc. | Dorling Janet
(Director) |
M | Common Stock | A | 6000 | $4.63 - $4.63 | $27,780 |
| 2024-01-24 | CymaBay Therapeutics, Inc. | Shantharam Harish
(Chief Financial Officer) |
A | Common Stock | A | 20125 | $0.00 - $0.00 | $0 |
| 2024-01-24 | CymaBay Therapeutics, Inc. | Dickinson Klara
(Chief Regulatory Officer) |
A | Common Stock | A | 21000 | $0.00 - $0.00 | $0 |
| 2024-01-24 | CymaBay Therapeutics, Inc. | McWherter Charles
(President of R&D) |
A | Common Stock | A | 31938 | $0.00 - $0.00 | $0 |
| 2024-01-24 | CymaBay Therapeutics, Inc. | Quinlan Paul T
(General Counsel) |
A | Common Stock | A | 28438 | $0.00 - $0.00 | $0 |
| 2024-01-24 | CymaBay Therapeutics, Inc. | Shah Sujal
(Chief Executive Officer) |
A | Common Stock | A | 96250 | $0.00 - $0.00 | $0 |
| 2024-01-19 | CymaBay Therapeutics, Inc. | McWherter Charles
(President of R&D) |
S | Common Stock | D | 18403 | $23.66 - $23.68 | $435,642 |
| 2024-01-19 | CymaBay Therapeutics, Inc. | McWherter Charles
(President of R&D) |
M | Common Stock | A | 18403 | $1.06 - $11.69 | $130,521 |
| 2024-01-16 | CymaBay Therapeutics, Inc. | Menold Daniel
(Vice President, Finance) |
S | Common Stock | D | 10000 | $23.58 - $23.58 | $235,806 |
| 2024-01-16 | CymaBay Therapeutics, Inc. | Menold Daniel
(Vice President, Finance) |
M | Common Stock | A | 10000 | $4.05 - $4.05 | $40,500 |
| 2024-01-16 | CymaBay Therapeutics, Inc. | Quinlan Paul T
(General Counsel) |
S | Common Stock | D | 5000 | $23.58 - $23.58 | $117,898 |
| 2024-01-16 | CymaBay Therapeutics, Inc. | Quinlan Paul T
(General Counsel) |
M | Common Stock | A | 5000 | $2.94 - $2.94 | $14,700 |
| 2024-01-10 | CymaBay Therapeutics, Inc. | Dorling Janet
(Director) |
S | Common Stock | D | 6000 | $23.86 - $23.86 | $143,144 |
| 2024-01-10 | CymaBay Therapeutics, Inc. | Dorling Janet
(Director) |
M | Common Stock | A | 6000 | $4.63 - $4.63 | $27,780 |
| 2023-11-17 | CymaBay Therapeutics, Inc. | McWherter Charles
(President of R&D) |
S | Common Stock | D | 11342 | $18.28 - $18.28 | $207,293 |
| 2023-11-17 | CymaBay Therapeutics, Inc. | McWherter Charles
(President of R&D) |
M | Common Stock | A | 11342 | $5.00 - $5.00 | $56,710 |
| 2023-11-15 | CymaBay Therapeutics, Inc. | Menold Daniel
(Vice President, Finance) |
S | Common Stock | D | 0 | $17.38 - $17.38 | $0 |
| 2023-11-15 | CymaBay Therapeutics, Inc. | Menold Daniel
(Vice President, Finance) |
M | Common Stock | A | 17500 | $3.45 - $3.45 | $60,375 |
| 2023-11-15 | CymaBay Therapeutics, Inc. | Quinlan Paul T
(General Counsel) |
S | Common Stock | D | 5000 | $17.38 - $17.38 | $86,889 |
| 2023-11-15 | CymaBay Therapeutics, Inc. | Quinlan Paul T
(General Counsel) |
M | Common Stock | A | 5000 | $2.94 - $2.94 | $14,700 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |